Cardiac cell-repair therapy: clinical issues

Nature Clinical Practice. Cardiovascular Medicine
Bernard J Gersh, Robert D Simari

Abstract

The possibility that cardiac cell-repair therapy might become a clinical reality is a challenge worthy of the current state of technological and scientific expertise at the start of the 21(st) century. The success of preclinical and early clinical studies is a strong inducement to move ahead with larger clinical trials, but caution is warranted given our lack of understanding of the potential mechanisms by which cell-repair therapy exerts a benefit on ventricular function, perfusion, and infarct size, irrespective of the type of cell, method, site, and disease entity. There are multiple clinical, mechanistic, and safety questions requiring answers, and these will be forthcoming only if the design of clinical trials is carefully tailored to answer specific questions. These questions, in turn, will require the use of different and multiple end points, depending on the specific issue and study. Accordingly, this review addresses the limitations of current clinical studies, the design of future trials, and the concept of a hierarchical series of end points that might provide answers to a host of different questions. Clinical and basic scientists need to approach the next generation of trials in partnership.

References

Oct 1, 1996·Annals of Internal Medicine·T R Fleming, D L DeMets
Dec 14, 2002·Circulation Research·Donald OrlicAndrew E Arai
Jul 16, 2003·Circulation·Frederick M RauscherDoris A Taylor
Dec 19, 2003·Journal of the American College of Cardiology·Raj R MakkarPeng-Sheng Chen
Mar 23, 2004·Nature·Kenneth R Chien
Jul 28, 2004·American Journal of Physiology. Heart and Circulatory Physiology·Denice M HodgsonAndre Terzic
Jan 22, 2005·The New England Journal of Medicine·Gust H BardyUNKNOWN Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators
Feb 5, 2005·Circulation Research·Kai C Wollert, Helmut Drexler
Nov 3, 2005·Nature Clinical Practice. Cardiovascular Medicine·Noel M Caplice, Arjun Deb
Nov 3, 2005·Nature Clinical Practice. Cardiovascular Medicine·Noel M CapliceJorge R Alegria
Nov 3, 2005·Nature Clinical Practice. Cardiovascular Medicine·Sorin V Pislaru, Robert D Simari
Dec 7, 2005·Circulation·John Alfred CarrRoberto M Lang

❮ Previous
Next ❯

Citations

Jun 19, 2010·Journal of Cardiovascular Translational Research·Simon MaltaisHung Q Ly
Feb 13, 2010·Heart, Lung & Circulation·Kenji FukushimaFrank M Bengel
Aug 9, 2006·The American Heart Hospital Journal·David R Holmes, Charanjit Rihal
Aug 2, 2008·Stem Cells·Satsuki YamadaAndre Terzic
Jan 2, 2007·Critical Care Nursing Quarterly·Sherrill A Shepler, Amit N Patel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.